MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:31Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Anticoagulants]]
			[[Category:Direct factor Xa inhibitors]]
			[[Category:DOACs]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #88

2026-05-23T03:42:09Z

parser-claude batch MedTemplate pre-fill, Top 300 #88

New page

{{MedTemplate
| generic = Rivaroxaban
| brand = Xarelto
| structure =
| classes = [[:Category:Anticoagulants|Anticoagulant]], [[:Category:Direct_factor_Xa_inhibitors|Direct factor Xa inhibitor]], [[:Category:DOACs|Direct oral anticoagulant (DOAC)]]
| uses = <vote slug="nvaf-stroke-prevention-use">Stroke prevention in nonvalvular atrial fibrillation</vote>, <vote slug="vte-treatment-use">VTE treatment</vote>, <vote slug="vte-prophylaxis-use">VTE prophylaxis after hip/knee replacement</vote>, <vote slug="cad-pad-low-dose-use">Low-dose with aspirin in stable CAD/PAD</vote>
| starting_dose = NVAF: 20 mg PO once daily with the evening meal (15 mg if CrCl 15-50); acute VTE: 15 mg BID for 21 days, then 20 mg daily; CAD/PAD: 2.5 mg BID with aspirin
| preparations = 2.5, 10, 15, 20 mg tablets
| fda_max = 30 mg/d (acute VTE first 21 days as 15 mg BID); otherwise 20 mg/d
| pill_id =
| routes = Oral
| onset = Peak anticoagulant effect 2-4 hours
| duration = 24 hours
| halflife = 5-9 hours (elderly: 11-13 hours)<ref name="xarelto-label">FDA Prescribing Information, Xarelto (rivaroxaban), Janssen, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/202439s037lbl.pdf</ref>
| bioavailability = ~80-100% with food at 15-20 mg doses (10 mg dose: ~80% without food); '''must be taken with food''' at therapeutic doses<ref name="xarelto-label" />
| pregnancy = Avoid in pregnancy; switch to LMWH. Crosses placenta; warfarin-class concerns about fetal hemorrhage and teratogenicity make heparins the preferred class.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="rivaroxaban-mech-claim">Rivaroxaban is a selective reversible direct inhibitor of activated factor X (Xa); blocking Xa interrupts thrombin generation at a stoichiometrically efficient point in the coagulation cascade, producing predictable anticoagulation without routine monitoring.</vote> CYP3A4 (primary) and P-glycoprotein substrate; strong dual inhibitors or inducers materially shift exposure. Reversal: andexanet alfa for life-threatening bleeding; 4F-PCC commonly used off-label when andexanet unavailable<ref name="xarelto-label" />.
}}

== References ==
<references />

Rivaroxaban - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #88